세계의 대상포진 백신 시장

Shingles Vaccines

발행일: 2024년 09월 | 리서치사:

Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 269 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

대상포진 백신 세계 시장은 2030년까지 45억 달러에 달할 것으로 전망

2023년 32억 달러로 추정되는 대상포진 백신 세계 시장은 2023-2030년의 분석 기간 동안 연평균 5.0% 성장하여 2030년에는 45억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 재조합 백신은 CAGR 5.1%를 기록하여 분석 기간 종료 시점에 39억 달러에 도달할 것으로 예상됩니다. 약독화 백신 분야의 성장률은 CAGR 4.2%로 추정됩니다.

미국 시장 8억 6,860만 달러, 중국은 CAGR 8.2%로 성장 전망

미국 대상포진 백신 시장은 2023년 8억 6,860만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023-2030년 8.2%의 연평균 복합 성장률(CAGR)로 2030년까지 9억 2,820만 달러 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 1.9%와 5.2%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 CAGR 3.0%로 성장할 것으로 예상됩니다.

세계 대상포진 백신 시장 - 주요 동향 및 촉진요인 요약

대상포진 백신의 구조와 주요 구성 성분은?

대상포진 백신은 수두와 같은 수두 대상포진 바이러스의 재활성화로 인해 발생하는 대상포진, 일반적으로 대상포진으로 알려진 대상포진으로부터 자신을 보호하기 위해 고안된 중요한 예방 도구입니다. 수두에 걸리면 바이러스는 체내에서 잠복해 있다가, 특히 노약자나 면역력이 저하된 사람에서 나중에 대상포진으로 재 활성화될 수 있습니다. 대상포진 백신은 바이러스에 대한 신체의 면역반응을 강화하여 재 활성화 가능성을 낮추고, 만약 발병하더라도 증상이 덜 심하게 나타날 수 있도록 돕습니다. 이 백신의 주요 성분은 비활성화 바이러스 입자 또는 바이러스 서브유닛으로, 질병을 유발하지 않고 면역 체계를 자극합니다. 유전자 재조합 대상포진 백신(RZV)과 같은 최신 대상포진 백신은 강력한 방어력을 제공하고 기존 제형에 비해 더 효과적이기 때문에 선호되고 있습니다. 이러한 백신은 보통 몇 달 간격으로 두 번 접종하여 바이러스에 대한 면역력을 장기간 유지하도록 합니다.

누가 대상포진 백신을 필요로 하는가?

대상포진 백신은 대상포진 및 그 합병증(대상포진 후 신경통(PHN) : 대상포진 발진이 치유된 후에도 오랫동안 지속되는 극심한 통증이 특징인 증상)에 걸릴 위험이 높은 50세 이상의 성인이나 면역력이 저하된 사람에게 특히 중요합니다. 대상포진은 심각한 불편함을 유발해 일상생활에 지장을 초래하고, 심할 경우 발진이 눈 근처에 생기면 시력 상실과 같은 합병증을 유발할 수 있기 때문에 예방접종은 매우 중요합니다. 노인의 경우, 나이가 들면서 면역체계가 감염과 싸우는 능력이 떨어지기 때문에 예방접종은 대상포진을 예방하는 효과적인 전략이 될 수 있습니다. 또한, 대상포진 백신은 암, HIV, 면역억제제 치료 등 면역체계가 저하되어 있는 사람들에게 대상포진으로 인한 면역력 약화 위험을 줄이기 위한 예방책이 포함되어 있습니다. 공중 보건 기관은 노인의 건강과 삶의 질을 유지하는 데 있어 대상포진 백신의 역할을 강조하며 대상자들에게 정기적인 예방 접종의 일환으로 대상포진 백신 접종을 강력히 권장하고 있습니다.

대상포진 백신의 최신 혁신과 동향은?

대상포진 백신 분야는 유효성, 접근성 및 환자 순응도 향상에 초점을 맞춘 지속적인 연구로 큰 진전을 이루고 있습니다. 가장 주목할 만한 동향 중 하나는 기존 약독성 생백신에 비해 더 높은 방어율과 더 오래 지속되는 면역력을 제공하는 보조제 재조합 대상포진 백신과 같은 재조합 백신의 개발입니다. 이러한 재조합 백신은 생백신이 적합하지 않은 면역 결핍 환자에게 특히 유리합니다. 또 다른 추세는 한 번의 접종으로 대상포진을 포함한 여러 질병을 예방할 수 있는 혼합 백신이 점점 더 많이 사용되고 있으며, 이는 예방접종 과정을 단순화하여 접종률을 높일 수 있습니다. 또한, 자가면역질환 환자나 장기이식 환자 등 고위험군에 대한 예방접종 권장 대상자를 확대하는 것에 대한 관심이 높아지고 있습니다. 또한, 더 적은 횟수의 접종으로 예방 효과를 발휘하는 백신이나 더 오랜 기간 예방 효과를 발휘하는 개량형 백신 개발을 위한 연구도 진행되고 있습니다. 이러한 기술 혁신은 대상포진 백신의 효과와 접근성을 높이고, 대상포진 부담을 줄이기 위한 광범위한 공중보건 노력에 기여하고 있습니다.

대상포진 백신 시장의 성장 원동력은?

대상포진 백신 시장의 성장은 몇 가지 요인에 의해 주도되고 있으며, 이는 이 고통스럽고 쇠약해질 수 있는 증상을 예방하는 데 있어 백신 접종의 중요성이 점점 더 많이 인식되고 있음을 반영합니다. 주요 요인 중 하나는 전 세계 인구의 고령화로 인해 대상포진과 그 합병증에 걸릴 확률이 높아짐에 따라 고령층에서 백신 접종에 대한 수요가 증가하고 있다는 점입니다. 백신 개발의 기술 발전, 특히 보다 효과적인 재조합 백신으로의 전환은 다양한 환자들에게 보다 안전하고 신뢰할 수 있는 선택권을 제공함으로써 시장 성장을 가속하고 있으며, CDC 및 WHO와 같은 보건 당국의 공중보건 노력과 권장사항은 대상포진 백신의 채택을 촉진하고 있습니다. 이들 기관은 대상포진과 관련된 막대한 의료 비용과 개인적 고통을 예방하기 위해 정기적인 백신 접종을 권장하고 있습니다. 또한, 대상포진 후 신경통과 같은 대상포진의 장기적인 영향에 대한 인식이 높아지면서 더 많은 사람들이 예방접종을 받도록 유도하고 있습니다. 신흥 시장에서의 의료 접근성 확대와 백신 접종 프로그램에 대한 정부 지원 확대도 전 세계 대상포진 백신 수요 증가에 기여하고 있습니다.

조사 대상 기업 예시(총 35건)

Barinthus Biotherapeutics plc
CanSino Biologics Inc.
Chongqing Zhifei Biological Products Co., Ltd
CSL Seqirus
Curevo Inc.
Geneone Life Science
GSK plc
INVC Wellness Pvt.
Jiangsu Recbio Technology Co.
Merck & Co.
Pfizer inc
RxDx Healthcare
SK bioscience
SK chemicals
목차

제1장 조사 방법

제2장 주요 요약

시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망

제3장 시장 분석

미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트(UAE)
기타 중동
아프리카

제4장 경쟁
LSH 24.09.23

Global Shingles Vaccines Market to Reach US$4.5 Billion by 2030

The global market for Shingles Vaccines estimated at US$3.2 Billion in the year 2023, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Live-Attenuated Vaccines segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$868.6 Million While China is Forecast to Grow at 8.2% CAGR

The Shingles Vaccines market in the U.S. is estimated at US$868.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$928.2 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Shingles Vaccines Market - Key Trends and Drivers Summarized

How Do Shingles Vaccines Work and What Are Their Key Components?

Shingles vaccines are critical preventive tools designed to protect against herpes zoster, commonly known as shingles, a painful viral infection caused by the reactivation of the varicella-zoster virus—the same virus responsible for chickenpox. Once a person has had chickenpox, the virus remains dormant in the body, potentially reactivating later in life as shingles, particularly in older adults and those with weakened immune systems. Shingles vaccines work by boosting the body's immune response to the virus, thereby reducing the likelihood of reactivation and the severity of symptoms if an outbreak does occur. The key components of these vaccines include inactivated viral particles or viral subunits that stimulate the immune system without causing illness. Modern shingles vaccines, such as the recombinant zoster vaccine (RZV), provide robust protection and are preferred due to their higher efficacy compared to older formulations. These vaccines are typically administered in a series of two doses, spaced several months apart, ensuring long-lasting immunity against the virus.

Who Needs Shingles Vaccines and Why Are They So Important?

Shingles vaccines are particularly important for adults aged 50 and older, as well as individuals with weakened immune systems, who are at increased risk of developing shingles and its complications, such as postherpetic neuralgia (PHN), a condition characterized by severe, long-lasting pain even after the shingles rash has healed. Vaccination is crucial because shingles can lead to significant discomfort, interfere with daily activities, and in severe cases, result in complications like vision loss if the rash occurs near the eyes. For older adults, the immune system's ability to fight infections weakens with age, making vaccination an effective strategy to prevent shingles. Additionally, for individuals with conditions that compromise the immune system—such as cancer, HIV, or those on immunosuppressive therapies—shingles vaccines offer a proactive measure to mitigate the risk of a debilitating shingles outbreak. Public health organizations strongly recommend shingles vaccination as part of routine preventive care for eligible populations, emphasizing its role in maintaining health and quality of life in older adults.

What Are the Latest Innovations and Trends in Shingles Vaccines?

The field of shingles vaccines has seen significant advancements, with ongoing research focused on improving efficacy, accessibility, and patient compliance. One of the most notable trends is the development of recombinant vaccines, such as the adjuvanted recombinant zoster vaccine, which provides higher protection rates and longer-lasting immunity compared to the older live attenuated vaccines. These recombinant vaccines are particularly advantageous for immunocompromised individuals who may not be suitable candidates for live vaccines. Another trend is the increasing availability of combination vaccines that protect against multiple diseases, including shingles, in a single shot, which can improve vaccination rates by simplifying the immunization process. Additionally, there is growing interest in expanding vaccination recommendations to younger populations at risk, such as those with autoimmune diseases or those undergoing organ transplants. Furthermore, ongoing research aims to develop vaccines that provide protection with fewer doses or enhanced formulations that offer even longer protection. These innovations are making shingles vaccines more effective and accessible, contributing to broader public health efforts to reduce the burden of herpes zoster.

What Is Driving the Growth of the Shingles Vaccines Market?

The growth in the shingles vaccines market is driven by several factors that reflect the increasing recognition of the importance of vaccination in preventing this painful and potentially debilitating condition. One of the primary drivers is the aging global population, which is more susceptible to shingles and its complications, leading to a higher demand for vaccination among older adults. Technological advancements in vaccine development, particularly the shift towards more effective recombinant vaccines, are also fueling market growth by providing safer and more reliable options for a broader range of patients. Public health initiatives and recommendations from health authorities, such as the CDC and WHO, are propelling the adoption of shingles vaccines, as these organizations advocate for routine vaccination to prevent the significant healthcare costs and personal suffering associated with shingles. Additionally, increased awareness of the long-term effects of shingles, such as postherpetic neuralgia, is encouraging more individuals to seek vaccination. The expansion of healthcare access in emerging markets, along with growing government support for vaccination programs, is also contributing to the rising demand for shingles vaccines globally.

Select Competitors (Total 35 Featured) -

Barinthus Biotherapeutics plc
CanSino Biologics Inc.
Chongqing Zhifei Biological Products Co., Ltd
CSL Seqirus
Curevo Inc.
Geneone Life Science
GSK plc
INVC Wellness Pvt. Ltd
Jiangsu Recbio Technology Co., Ltd
Merck & Co., Inc.
Pfizer inc
RxDx Healthcare
SK bioscience
SK chemicals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

Shingles Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS

Aging Population Propels Growth in Shingles Vaccines Market

Increased Awareness of Postherpetic Neuralgia Drives Adoption of Shingles Vaccines

Advancements in Vaccine Development Strengthen Business Case for Recombinant Shingles Vaccines

Expanding Immunization Guidelines Expands Addressable Market Opportunity for Shingles Vaccines

Rising Incidence of Immunocompromising Conditions Generates Demand for More Effective Shingles Vaccines

Growing Focus on Preventive Healthcare Spurs Growth in Shingles Vaccines Market

Vaccine Supply Chain Innovations Sustain Growth in Global Shingles Vaccination Efforts

Shift Towards Combination Vaccines Expands Market Potential for Shingles Vaccines

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: World Shingles Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Shingles Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Live-Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Live-Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Live-Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)

TABLE 20: USA Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 23: USA Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: USA Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: USA 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

CANADA

TABLE 26: Canada Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 29: Canada Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Canada 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

JAPAN

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)

TABLE 32: Japan Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 35: Japan Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Japan 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

CHINA

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)

TABLE 38: China Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: China Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: China 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 41: China Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: China Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: China 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

EUROPE

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)

TABLE 44: Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Shingles Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Europe 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

FRANCE

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)

TABLE 53: France Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: France Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: France 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 56: France Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: France Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: France 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

GERMANY

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)

TABLE 59: Germany Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Germany 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 62: Germany Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Germany 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

ITALY

TABLE 65: Italy Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Italy 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 68: Italy Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Italy 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

UNITED KINGDOM

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)

TABLE 71: UK Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: UK Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: UK 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 74: UK Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: UK Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: UK 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

SPAIN

TABLE 77: Spain Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Spain Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Spain 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 80: Spain Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Spain Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Spain 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

RUSSIA

TABLE 83: Russia Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Russia Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Russia 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 86: Russia Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Russia Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Russia 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

REST OF EUROPE

TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of Europe Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of Europe 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of Europe 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)

TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 96: Asia-Pacific Historic Review for Shingles Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Asia-Pacific 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Asia-Pacific 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

AUSTRALIA

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)

TABLE 104: Australia Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Australia Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Australia 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 107: Australia Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Australia Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Australia 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

INDIA

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)

TABLE 110: India Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: India Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: India 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 113: India Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: India Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: India 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

SOUTH KOREA

TABLE 116: South Korea Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: South Korea Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: South Korea 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 119: South Korea Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: South Korea Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: South Korea 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

REST OF ASIA-PACIFIC

TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of Asia-Pacific Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: Rest of Asia-Pacific Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

LATIN AMERICA

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)

TABLE 128: Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 129: Latin America Historic Review for Shingles Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Latin America 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 131: Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Latin America Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Latin America 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 134: Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

ARGENTINA

TABLE 137: Argentina Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Argentina Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Argentina 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 140: Argentina Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Argentina Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Argentina 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

BRAZIL

TABLE 143: Brazil Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Brazil Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Brazil 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 146: Brazil Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Brazil Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Brazil 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

MEXICO

TABLE 149: Mexico Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Mexico Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Mexico 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 152: Mexico Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Mexico Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Mexico 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

REST OF LATIN AMERICA

TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Rest of Latin America Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Rest of Latin America 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Rest of Latin America Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Rest of Latin America 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

MIDDLE EAST

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)

TABLE 161: Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 162: Middle East Historic Review for Shingles Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Middle East 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 164: Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Middle East Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Middle East 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 167: Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IRAN

TABLE 170: Iran Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Iran Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Iran 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 173: Iran Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Iran Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Iran 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

ISRAEL

TABLE 176: Israel Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Israel Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Israel 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 179: Israel Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Israel Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Israel 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

SAUDI ARABIA

TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Saudi Arabia Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Saudi Arabia 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Saudi Arabia Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Saudi Arabia 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

UNITED ARAB EMIRATES

TABLE 188: UAE Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: UAE Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: UAE 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 191: UAE Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: UAE Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: UAE 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

REST OF MIDDLE EAST

TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Rest of Middle East Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Rest of Middle East 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Rest of Middle East Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Rest of Middle East 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

AFRICA

Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)

TABLE 200: Africa Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Africa Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Africa 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
TABLE 203: Africa Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Africa Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Africa 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION